Literature DB >> 1449240

Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.

T G Nygaard1, H Takahashi, G A Heiman, B J Snow, S Fahn, D B Calne.   

Abstract

Dopa-responsive dystonia (DRD) is one form of childhood-onset idiopathic torsion dystonia. Adult-onset parkinsonism has appeared in several previously unaffected members in families with DRD suggesting that this may be an additional phenotypical expression of the disease. We report a family with DRD in which 2 women and 1 man, unaffected by dystonia, developed tremor-onset parkinsonism after age 50 years. The women continue on a low dosage of levodopa after 9 and 13 years of treatment, with a stable, nearly complete, symptomatic response. This contrasts to the typical long-term treatment complications observed in patients with Parkinson's disease. We assessed nigrostriatal dopaminergic function in the proband, with typical DRD, and the 2 women with parkinsonism using 6-[18F]fluoro-L-dopa positron emission tomography. All 3 had normal striatal 6-[18F]fluoro-L-dopa uptake. These observations provide compelling evidence that "benign" adult-onset parkinsonism may be an expression of the disease in some members of families with DRD and does not support consideration of the DRD gene as a risk factor for development of Parkinson's disease. There may be considerable clinical heterogeneity in DRD depending on the age at onset.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449240     DOI: 10.1002/ana.410320502

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

2.  Dystonia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia.

Authors:  Yoshiaki Furukawa; Stephen J Kish
Journal:  Brain       Date:  2014-11-21       Impact factor: 13.501

4.  GCH1 mutations in dopa-responsive dystonia and Parkinson's disease.

Authors:  Hiroyo Yoshino; Kenya Nishioka; Yuanzhe Li; Yutaka Oji; Genko Oyama; Taku Hatano; Yutaka Machida; Yasushi Shimo; Arisa Hayashida; Aya Ikeda; Kaoru Mogushi; Yasuro Shibagaki; Ai Hosaka; Hiroshi Iwanaga; Junko Fujitake; Takekazu Ohi; Daigo Miyazaki; Yoshiki Sekijima; Mitsuaki Oki; Hirofumi Kusaka; Ken-Ichi Fujimoto; Yoshikazu Ugawa; Manabu Funayama; Nobutaka Hattori
Journal:  J Neurol       Date:  2018-06-14       Impact factor: 4.849

Review 5.  Dopa-responsive dystonia--clinical and genetic heterogeneity.

Authors:  Subhashie Wijemanne; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

6.  Treatment of generalized dystonia.

Authors:  Naomi Lubarr; Susan Bressman
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

7.  SKN-1/Nrf2 inhibits dopamine neuron degeneration in a Caenorhabditis elegans model of methylmercury toxicity.

Authors:  Natalia Vanduyn; Raja Settivari; Garry Wong; Richard Nass
Journal:  Toxicol Sci       Date:  2010-09-20       Impact factor: 4.849

8.  Lessons from a remarkable family with dopa-responsive dystonia.

Authors:  G Harwood; R Hierons; N A Fletcher; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

9.  Two novel mutations of the GTP cyclohydrolase 1 gene and genotype-phenotype correlation in Chinese Dopa-responsive dystonia patients.

Authors:  Lihua Yu; Huayong Zhou; Fayun Hu; Yanming Xu
Journal:  Eur J Hum Genet       Date:  2012-12-05       Impact factor: 4.246

Review 10.  Combined dystonias: clinical and genetic updates.

Authors:  Anne Weissbach; Gerard Saranza; Aloysius Domingo
Journal:  J Neural Transm (Vienna)       Date:  2020-10-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.